XML 58 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value Measurements (Additional Information) (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2024
Sep. 30, 2023
Apr. 30, 2023
Oct. 31, 2024
Sep. 30, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Oct. 08, 2024
Subsidiary, Sale of Stock [Line Items]                    
Note discount rate           12907.00%   128.82% 13.05%  
Principle amount of issued debt     $ 25,000,000              
Warrants outstanding               5,467,692 6,854,309  
Derivative warrant liabilities           $ 7,900,000   $ 18,300,000    
Accumulated other comprehensive income           6,317,000   6,317,000 $ 0  
Purchased revenue liability           7,300,000   6,800,000   $ 5,900,000
(Gain) loss on derivative liability           10,409,000 $ (457,000) 17,378,000 (512,000)  
Common stock upon conversation of cash           $ 3,000,000   $ 3,000,000    
Discount rate of FDA           9.60%   10.00%    
Development Milestone Payment           $ 200,000   $ 200,000 200,000  
Warrants                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           5,467,692   156,220    
(Gain) loss on derivative liability           $ 10,400 500,000 $ 17,400,000 (500,000)  
Convertible Debentures                    
Subsidiary, Sale of Stock [Line Items]                    
(Gain) loss on derivative liability               35,000 4,400,000  
Oramed Note                    
Subsidiary, Sale of Stock [Line Items]                    
Estimated fair value           15,000,000   12,200,000 104,100,000  
Principle amount of issued debt $ 10,000,000 $ 101,900,000     $ 101,900,000          
Accumulated other comprehensive income               5,000,000    
Change in fair value of debt and liability instruments           2,800,000 $ 3,800,000 3,600,000 2,800,000  
Change in fair value due to credit risk               6,300,000 $ 0  
Tranche BNotes Member                    
Subsidiary, Sale of Stock [Line Items]                    
Estimated fair value           24,500,000   23,600,000    
Principle amount of issued debt       $ 50,000,000            
Change in fair value of debt and liability instruments           2,500,000   6,600,000    
Purchased Revenue Liability                    
Subsidiary, Sale of Stock [Line Items]                    
Change in fair value of debt and liability instruments           800,000   900,000    
FSF Deposit Member                    
Subsidiary, Sale of Stock [Line Items]                    
Change in fair value of debt and liability instruments               4,700,000    
Gloperba Elyxyb Royalty Purchase Agreement                    
Subsidiary, Sale of Stock [Line Items]                    
Purchased revenue liability           $ 7,300,000   $ 6,800,000    
Private Placement                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           1,000,000   1,000,000    
Private Placement | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           28,572   28,572    
February 2024 BDO Firm Warrants [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           3,803,447   3,803,447    
February 2024 BDO Firm Warrants [Member] | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           108,686   108,686    
April 2024 RDO Common Warrants [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           15,000,000   15,000,000    
April 2024 RDO Common Warrants [Member] | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           428,572   428,572    
Deposit Warrants                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           3,250,000   3,250,000    
Deposit Warrants | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           3,250,000   3,250,000    
October 2024 Noteholder Warrants                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           7,500,000   7,500,000    
October 2024 Noteholder Warrants | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           214,284   214,284    
December 2024 RDO Common Warrants                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           57,512,958   57,512,958    
December 2024 RDO Common Warrants | Common Stock                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding           1,642,871   1,642,871